Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without Adjuvants

The immunogenicity results from 3 phase I trials of the Merck DNA human immunodeficiency virus (HIV) vaccine have previously been reported. Because preventive DNA vaccine strategies continue to be leveraged for diverse infections, the safety and tolerability results from these studies can inform the...

Descripción completa

Detalles Bibliográficos
Autores principales: Quirk, Erin K., Brown, Elizabeth L., Leavitt, Randi Y., Mogg, Robin, Mehrotra, Devan V., Evans, Robert K., DiNubile, Mark J., Robertson, Michael N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324197/
https://www.ncbi.nlm.nih.gov/pubmed/25734089
http://dx.doi.org/10.1093/ofid/ofu016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324197/
https://www.ncbi.nlm.nih.gov/pubmed/25734089
http://dx.doi.org/10.1093/ofid/ofu016

Ejemplares similares